teamLab Planets TOKYO Reveals Entirety of the Newly Expanded Area, Featuring “Catching and Collecting Forest” and “Athletics Forest”. Opening January 22
21.1.2025 19:00:00 EET | Business Wire | Press release
A new large-scale Athletics Forest and more artworks will open at teamLab Planets TOKYO DMM in Toyosu, Tokyo (teamLab Planets) on January 22, 2025.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250120453018/en/
teamLab, Catching and Collecting Extinct Forest (c) teamLab - There are various extinct animals that live in this Extinct Forest. When you move close to the animals or touch them, they will run away or turn to face you.
teamLab Planets increases its area by 1.5 times, creating an extensive new space to introduce teamLab’s educational projects. The new additions include Athletics Forest, a complex, multi-dimensional creative athletic space; Catching and Collecting Extinct Forest where visitors can capture and study extinct animals; and Future Park, a collaborative space for co-creation. Over 20 new artworks will be exhibited.
In addition, new spaces have been introduced to the museum, such as the Orchid Glass House, where visitors can enjoy tea and drinks surrounded by orchids; the Living Art Store, where visitors can take home regrown orchids; and Sketch Factory, where visitors’ drawings created within the artwork space are transformed into original products to take home. The outdoor area featuring the Black Emptiness Table, where visitors can enjoy Vegan Ramen UZU Tokyo, will also undergo a major renovation.
Tickets through March 2025 are now available on the official website.
teamLab Planets TOKYO DMM
https://www.teamlab.art/e/planets/
#teamLabPlanets
July 7, 2018 - End of 2027
Toyosu, Tokyo (teamLab Planets TOKYO, Toyosu 6-1-16, Koto-ku, Tokyo)
Highlight Video
https://youtu.be/F7nODEETR4s
Press kit
https://www.dropbox.com/sh/ir7d2aui794eo6z/AAChbzX5wPsQm8cgkQ2ViFD4a?dl=0
View source version on businesswire.com: https://www.businesswire.com/news/home/20250120453018/en/
Contacts
teamLab Planets PR Department
E-MAIL: pr-info@planets.art
For interview enquiries: https://forms.gle/fAtnDKLpQKFME6XR9 -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fforms.gle%2FfA
tnDKLpQKFME6XR9&esheet=54183215&newsitemid=20250120453018&lan=en-US&anchor=https
%3A%2F%2Fforms.gle%2FfAtnDKLpQKFME6XR9&index=7&md5=5ee9967d2ddfb6f1a9b18144972ae
6f9
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 10:00:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced deep tech executive with more than 25 years delivering products across multiple industries from startups to Fortune 500 companies, will advance IQM's technology strategy and drive its implementation into systems and products. De Vega, meanwhile, will be responsible for ensuring scientific feasibility and system-level
Teijin Receives Approval for Additional Indications of XEOMIN ® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 10:00:00 EEST | Press release
Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 09:00:00 EEST | Press release
Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L
Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 20:07:00 EEST | Press release
Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Helio Strap Pro represents the next evolution of Amazfit's Hybrid Training System, extending performance tracking beyond heart rate to help athletes bett
HyperLight Announces $80 Million Series C to Accelerate TFLN Deployment for AI Infrastructure18.6.2026 18:30:00 EEST | Press release
HyperLight Corporation (“HyperLight”), a leader in thin-film lithium niobate (TFLN) photonics, today announced the closing of an $80 million Series C financing round led by MediaTek. The round includes participation from UMC Capital, Jabil, Foxconn, EDBI (arm of SG Growth Capital, the investment platform of the Singapore Economic Development Board and Enterprise Singapore), CDIB-TEN Capital, and Qatar Investment Authority (QIA), as well as strategic investors from leading silicon IC and networking companies. Existing investors Summit Partners, The Engine, Foothill Ventures, and Xora Innovation continue to actively support the company’s growth. The financing brings together companies across the AI infrastructure value chain — including silicon ICs, foundry manufacturing, electronics manufacturing services, networking, and global infrastructure investment — reflecting broad ecosystem support for scaling TFLN photonics into production. “This financing is about more than capital — it is ab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom